Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis

被引:322
|
作者
Reed, Caitlin [1 ]
Bryant, Richard [2 ,3 ]
Ibrahim, Ashraf S. [1 ,3 ]
Edwards, John, Jr. [1 ,3 ]
Filler, Scott G. [1 ,3 ]
Goldberg, Robert [2 ,3 ]
Spellberg, Brad [1 ,3 ]
机构
[1] Harbor UCLA Med Ctr, Div Infect Dis, Los Angeles Biomed Res Inst, Torrance, CA 90509 USA
[2] Univ Calif Los Angeles, Med Ctr, Dept Orbital & Ophthalm Plast Surg, Los Angeles, CA 90024 USA
[3] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
关键词
D O I
10.1086/589857
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. It has been axiomatic that echinocandins ( e. g., caspofungin) are ineffective against mucormycosis. However, on the basis of preclinical data, we recently began treating rhino- orbital- cerebral mucormycosis ( ROCM) with combination polyene- caspofungin therapy. Methods. To determine the impact of polyene-caspofungin therapy, ROCM cases identified by an International Classification of Diseases, Ninth Revision search were retrospectively reviewed to gather data on demographic characteristics, clinical history, and outcomes. The predefined primary end point was success (i.e., the patients was alive and not in hospice care) at 30 days after hospital discharge. Results. Forty-one patients with biopsy-proven ROCM were identified over 12 years; 23 (56%) of these patients were Hispanic, and 34 (83%) were diabetic. Patients treated with polyene-caspofungin therapy (6 evaluable patients) had superior success (100% vs. 45%; P = .02) and Kaplan-Meier survival time (P = .02), compared with patients treated with polyene monotherapy. Patients treated with amphotericin B lipid complex had inferior success (37% vs. 72%; P= .03) and a higher clinical failure rate (45% vs. 21%; P = .04), compared with patients who received other polyenes. However, patients treated with amphotericin B lipid complex plus caspofungin had superior success (100% vs. 20%; P = .009) and survival time (P = .01), compared with patients who received amphotericin B lipid complex alone. The benefit of combination therapy, compared with monotherapy, was most pronounced in patients with cerebral involvement (success rate, 100% vs. 25%; P = .01). In multivariate analysis, only receipt of combination therapy was significantly associated with improved outcomes (odds ratio, 10.9; 95% confidence interval, 1.3-infinity; P = .02). Conclusions. Combination polyene-caspofungin therapy represents a promising potential alternative to polyene monotherapy for patients with ROCM. Randomized, prospective investigation of these findings is warranted.
引用
收藏
页码:364 / 371
页数:8
相关论文
共 50 条
  • [41] The ROC Staging System for COVID-related Rhino-Orbital-Cerebral Mucormycosis
    Naik, Milind N.
    Rath, Suryasnata
    SEMINARS IN OPHTHALMOLOGY, 2022, 37 (03) : 279 - 283
  • [42] Predisposing factors of rhino-orbital-cerebral mucormycosis in patients with COVID 19 infection
    Pradhan, Pradeep
    Shaikh, Zaid
    Mishra, Abhijeet
    Preetam, C.
    Parida, Pradipta Kumar
    Sarkar, Sourav
    Samal, Dillip Kumar
    Nayak, Anindya
    Chadaram, Srinivas
    Das, Krishna Kinkar
    Chakraborty, Swagata
    Sharma, Prity
    Aswathi, K., V
    Vinusree, K.
    Mittal, Yash
    Sundaram, Kalyana
    Swarup, Anurita
    Adhikari, Asutosh
    Chenniappan, Swathi
    Shah, Anwer
    INDIAN JOURNAL OF OTOLARYNGOLOGY AND HEAD & NECK SURGERY, 2022, 74 (SUPPL 2) : 3151 - 3157
  • [43] Effect of the staging of rhino-orbital-cerebral mucormycosis on its management and clinical outcome
    Raj, Anuradha
    Gupta, Vikas
    Krishnamoorthi, Sivanantham
    Kaur, Harmeet
    Saini, Vaibhav
    INDIAN JOURNAL OF OPHTHALMOLOGY, 2024, 72 (10) : 1519 - 1523
  • [44] Transcutaneous retrobulbar injection of amphotericin B in rhino-orbital-cerebral mucormycosis: a review
    Nair, Akshay Gopinathan
    Dave, Tarjani Vivek
    ORBIT-THE INTERNATIONAL JOURNAL ON ORBITAL DISORDERS-OCULOPLASTIC AND LACRIMAL SURGERY, 2022, 41 (03): : 275 - 286
  • [45] Bilateral blindness in a young male of rhino-orbital-cerebral mucormycosis: A case report
    Kaur, Rajwinder
    Sehgal, Akriti
    Khan, Balbir
    Budhiraja, Grace
    Roychoudhury, Arnav Kr
    Kaur, Manjot
    INDIAN JOURNAL OF OPHTHALMOLOGY, 2022, 70 (05) : 1822 - 1824
  • [46] Predisposing factors of rhino-orbital-cerebral mucormycosis in patients with COVID 19 infection
    Pradeep Pradhan
    Zaid Shaikh
    Abhijeet Mishra
    C. Preetam
    Pradipta Kumar Parida
    Sourav Sarkar
    Dillip Kumar Samal
    Anindya Nayak
    Srinivas Chadaram
    Krishna Kinkar Das
    Swagata Chakraborty
    Prity Sharma
    K. V. Aswathi
    K. Vinusree
    Yash Mittal
    Kalyana Sundaram
    Anurita Swarup
    Asutosh Adhikari
    Swathi Chenniappan
    Anwer Shah
    Indian Journal of Otolaryngology and Head & Neck Surgery, 2022, 74 : 3151 - 3157
  • [47] Is mucormycosis the end? A comprehensive management of orbit in COVID associated rhino-orbital-cerebral mucormycosis: preserving the salvageable
    Keshri, Amit
    Mathialagan, Arulalan
    Aishwarya, Ankita
    Ravisankar
    Bhuskute, Govind
    Kanaujia, Vikas
    Singh, A. K.
    Singh, R. K.
    Dhiman, R. K.
    Agarwal, Rachna
    EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, 2023, 280 (02) : 819 - 827
  • [48] Post Covid-19 rhino-orbital-cerebral mucormycosis presenting as unilateral headache
    Dubey, A.
    Dubey, S.
    JOURNAL OF HEADACHE AND PAIN, 2021, 22 (SUPPL 2):
  • [49] Post Covid-19 rhino-orbital-cerebral mucormycosis presenting as unilateral headache
    Dubey, A.
    Dubey, S.
    CEPHALALGIA, 2021, 41 (1_SUPPL) : 243 - 243
  • [50] COVID-19-Related Rhino-Orbital-Cerebral Mucormycosis With Angioinvasion: A Lethal Sequelae
    Redzuwan, Nur Syazwani
    Kumarakulasinghe, Andrea Lillianne Barr
    Kasim, Wan Mariny W. Md
    Khialdin, Safinaz Mohd
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (06)